|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seiwert TY and Cohen EE: State-of-the-art
management of locally advanced head and neck cancer. Br J Cancer.
92:1341–1348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vermorken JB, Remenar E, van Herpen C,
Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss
JH, et al EORTC 24971/TAX 323 Study Group: Cisplatin, fluorouracil,
and docetaxel in unresectable head and neck cancer. N Engl J Med.
357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prestwich RJ, Öksüz DÇ, Dyker K, Coyle C
and Şen M: Feasibility and efficacy of induction docetaxel,
cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin
concurrent chemoradiotherapy for nonmetastatic Stage IV
head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol
Phys. 81:e237–e243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boman BM and Wicha MS: Cancer stem cells:
A step toward the cure. J Clin Oncol. 26:2795–2799. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Davis SJ, Divi V, Owen JH, Bradford CR,
Carey TE, Papagerakis S and Prince ME: Metastatic potential of
cancer stem cells in head and neck squamous cell carcinoma. Arch
Otolaryngol Head Neck Surg. 136:1260–1266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitani M, Yamanishi T and Miyazaki Y:
Salinomycin: A new monovalent cation ionophore. Biochem Biophys Res
Commun. 66:1231–1236. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huczynski A: Salinomycin: A new cancer
drug candidate. Chem Biol Drug Des. 79:235–238. 2012. View Article : Google Scholar
|
|
10
|
Riccioni R, Dupuis ML, Bernabei M,
Petrucci E, Pasquini L, Mariani G, Cianfriglia M and Testa U: The
cancer stem cell selective inhibitor salinomycin is a
p-glycoprotein inhibitor. Blood Cells Mol Dis. 45:86–92. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boehmerle W and Endres M: Salinomycin
induces calpain and cytochrome c-mediated neuronal cell death. Cell
Death Dis. 2:e1682011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rangan SR: A new human cell line (FaDu)
from a hypopharyngeal carcinoma. Cancer. 29:117–121. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmidt M, Polednik C, Gruensfelder P,
Roller J and Hagen R: The effects of PC-Spes on chemosensitive and
chemoresistant head and neck cancer cells and primary mucosal
keratinocytes. Oncol Rep. 21:1297–1305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zenner HP, Lehner W and Herrmann IF:
Establishment of carcinoma cell lines from larynx and submandibular
gland. Arch Otorhinolaryngol. 225:269–277. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fuchs D, Heinold A, Opelz G, Daniel V and
Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis
resistance in human cancer cells. Biochem Biophys Res Commun.
390:743–749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang GN, Liang Y, Zhou LJ, Chen SP, Chen
G, Zhang TP, Kang T and Zhao YP: Combination of salinomycin and
gemcitabine eliminates pancreatic cancer cells. Cancer Lett.
313:137–144. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ
and Carson DA: Salinomycin inhibits Wnt signaling and selectively
induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl
Acad Sci USA. 108:13253–13257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arafat K, Iratni R, Takahashi T, Parekh K,
Al Dhaheri Y, Adrian TE and Attoub S: Inhibitory Effects of
Salinomycin on Cell Survival, Colony Growth, Migration, and
Invasion of Human Non-Small Cell Lung Cancer A549 and LNM35:
Involvement of NAG-1. PLoS One. 8:e669312013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou S, Wang F, Wong ET, Fonkem E, Hsieh
TC, Wu JM and Wu E: Salinomycin: A novel anti-cancer agent with
known anti-coccidial activities. Curr Med Chem. 20:4095–4101. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Story P and Doube A: A case of human
poisoning by salinomycin, an agricultural antibiotic. N Z Med J.
117:U7992004.PubMed/NCBI
|
|
23
|
Scherzed A, Hackenberg S, Froelich K, Rak
K, Technau A, Radeloff A, Nöth U, Koehler C, Hagen R and
Kleinsasser N: Effects of salinomycin on human bone marrow-derived
mesenchymal stem cells in vitro. Toxicol Lett. 218:207–214. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mitani M, Yamanishi T, Miyazaki Y and
Otake N: Salinomycin effects on mitochondrial ion translocation and
respiration. Antimicrob Agents Chemother. 9:655–660. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kodama A, Watanabe H, Tanaka R, Kondo M,
Chuang VT, Wu Q, Endo M, Ishima Y, Fukagawa M, Otagiri M, et al:
Albumin fusion renders thioredoxin an effective anti-oxidative and
anti-inflammatory agent for preventing cisplatin-induced
nephrotoxicity. Biochim Biophys Acta. 1840:1152–1162. 2014.
View Article : Google Scholar
|
|
26
|
Kojouharov BM, Brackett CM, Veith JM,
Johnson CP, Gitlin II, Toshkov IA, Gleiberman AS, Gudkov AV and
Burdelya LG: Toll-like receptor-5 agonist Entolimod broadens the
therapeutic window of 5-fluorouracil by reducing its toxicity to
normal tissues in mice. Oncotarget. 5:802–814. 2014.PubMed/NCBI
|
